| Quarter | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| 67 | 80 | 85 | |
Growth YoY Revenue Growth YoY% | 27.9 | ||
| 52 | 65 | 67 | |
| 15 | 15 | 18 | |
OPM OPM% | 22.0 | 19.0 | 21.5 |
| 0 | 1 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 |
Depreciation DepreciationCr | 2 | 2 | 2 |
PBT PBTCr | 15 | 16 | 19 |
| 3 | 4 | 4 | |
| 10 | 11 | 12 | |
Growth YoY PAT Growth YoY% | 20.0 | ||
NPM NPM% | 15.0 | 13.2 | 14.1 |
| 4.8 | 4.5 | 5.2 |
| Quarter | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| 67 | 80 | 85 | |
Growth YoY Revenue Growth YoY% | 27.9 | ||
| 52 | 65 | 67 | |
| 15 | 15 | 18 | |
OPM OPM% | 22.0 | 19.0 | 21.5 |
| 0 | 1 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 |
Depreciation DepreciationCr | 2 | 2 | 2 |
PBT PBTCr | 15 | 16 | 19 |
| 3 | 4 | 4 | |
| 10 | 11 | 12 | |
Growth YoY PAT Growth YoY% | 20.0 | ||
NPM NPM% | 15.0 | 13.2 | 14.1 |
| 4.8 | 4.5 | 5.2 |
| Financial Year | Mar 2026 | TTM |
|---|---|---|
Revenue RevenueCr | 147 | 165 |
Growth Revenue Growth% | ||
| 117 | 132 | |
| 30 | 34 | |
OPM OPM% | 20.3 | 20.3 |
| 1 | 2 | |
Interest Expense Interest ExpenseCr | 0 | 0 |
Depreciation DepreciationCr | 4 | 4 |
PBT PBTCr | 27 | 35 |
| 7 | 7 | |
PAT PATCr | 21 | 23 |
Growth PAT Growth% | ||
NPM NPM% | 14.0 | 13.6 |
| 9.3 | 9.7 |
| Financial Year | Mar 2026 | TTM |
|---|---|---|
Revenue RevenueCr | 147 | 165 |
Growth Revenue Growth% | ||
| 117 | 132 | |
| 30 | 34 | |
OPM OPM% | 20.3 | 20.3 |
| 1 | 2 | |
Interest Expense Interest ExpenseCr | 0 | 0 |
Depreciation DepreciationCr | 4 | 4 |
PBT PBTCr | 27 | 35 |
| 7 | 7 | |
PAT PATCr | 21 | 23 |
Growth PAT Growth% | ||
NPM NPM% | 14.0 | 13.6 |
| 9.3 | 9.7 |
| Financial Year | Mar 2026 | Sep 2026 |
|---|---|---|
Equity Capital Equity CapitalCr | 23 | 23 |
Reserves ReservesCr | 78 | 90 |
| 23 | ||
| 0 | ||
| 124 | 141 | |
| 81 | ||
| 42 | ||
| 124 | 141 |
| Financial Year | Mar 2026 | Sep 2026 |
|---|---|---|
Equity Capital Equity CapitalCr | 23 | 23 |
Reserves ReservesCr | 78 | 90 |
| 23 | ||
| 0 | ||
| 124 | 141 | |
| 81 | ||
| 42 | ||
| 124 | 141 |
| Financial Year | Mar 2026 |
|---|---|
| 4 | |
| -25 | |
| 45 | |
Net Cash Flow Net Cash FlowCr | 23 |
Free Cash Flow Free Cash FlowCr | -21 |
CFO To PAT CFO To PAT% | 18.9 |
CFO To EBITDA CFO To EBITDA% | 13.0 |
| Financial Year | Mar 2026 |
|---|---|
| 4 | |
| -25 | |
| 45 | |
Net Cash Flow Net Cash FlowCr | 23 |
Free Cash Flow Free Cash FlowCr | -21 |
CFO To PAT CFO To PAT% | 18.9 |
CFO To EBITDA CFO To EBITDA% | 13.0 |
| Financial Year | Mar 2026 | Current |
|---|---|---|
Market Cap Market CapitalizationCr | 468 | 660 |
Price To Earnings Price To Earnings | 22.8 | 29.3 |
Price To Sales Price To Sales | 3.2 | 4.0 |
Price To Book Price To Book | 4.6 | 6.5 |
EV To EBITDA EV To EBITDA | 14.8 | 18.9 |
GPM GPM% | 33.1 | 33.1 |
OPM OPM% | 20.3 | 20.3 |
NPM NPM% | 14.0 | 13.6 |
ROCE ROCE% | 27.2 | 31.1 |
ROE ROE% | 20.4 | 20.0 |
ROA ROA% | 16.6 | 16.0 |
| Financial Year | Mar 2026 | Current |
|---|---|---|
Market Cap Market CapitalizationCr | 468 | 660 |
Price To Earnings Price To Earnings | 22.8 | 29.3 |
Price To Sales Price To Sales | 3.2 | 4.0 |
Price To Book Price To Book | 4.6 | 6.5 |
EV To EBITDA EV To EBITDA | 14.8 | 18.9 |
GPM GPM% | 33.1 | 33.1 |
OPM OPM% | 20.3 | 20.3 |
NPM NPM% | 14.0 | 13.6 |
ROCE ROCE% | 27.2 | 31.1 |
ROE ROE% | 20.4 | 20.0 |
ROA ROA% | 16.6 | 16.0 |
| Market CapitalizationMkt CapCr | 874 | 793 | 782 | 660 | 486 | 435 | 402 |
| Close PriceClose₹ | 94.87 | 147.80 | 223.81 | 285.00 | 406.05 | 762.60 | 285.90 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 17.25 | 278.87 | 32.16 | 29.26 | 20.89 | 15.14 | 32.16 |
| Price To SalesPS | 2.54 | 1.92 | 3.28 | 3.99 | 3.11 | 1.15 | 1.91 |
| RevenueRevenueCr | 343 | 414 | 239 | 165 | 156 | 378 | 210 |
| Revenue Growth TTMRev Gr TTM% | 0.7% | 13.1% | 13.9% | 55.2% | 19.7% | 27.5% | |
| PAT Growth TTMPAT Gr TTM% | 287.7% | -68.6% | -13.6% | 39.5% | 290.6% | 41.9% |
| Market CapitalizationMkt CapCr | 874 | 793 | 782 | 660 | 486 | 435 | 402 |
| Close PriceClose₹ | 94.87 | 147.80 | 223.81 | 285.00 | 406.05 | 762.60 | 285.90 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 17.25 | 278.87 | 32.16 | 29.26 | 20.89 | 15.14 | 32.16 |
| Price To SalesPS | 2.54 | 1.92 | 3.28 | 3.99 | 3.11 | 1.15 | 1.91 |
| RevenueRevenueCr | 343 | 414 | 239 | 165 | 156 | 378 | 210 |
| Revenue Growth TTMRev Gr TTM% | 0.7% | 13.1% | 13.9% | 55.2% | 19.7% | 27.5% | |
| PAT Growth TTMPAT Gr TTM% | 287.7% | -68.6% | -13.6% | 39.5% | 290.6% | 41.9% |